A collection of extraordinary essays on key issues in the natural sciences

GOTTFRIED SCHATZ

A MATTER OF WONDER

WHAT BIOLOGY REVEALS ABOUT US, OUR WORLD, AND OUR DREAMS

Where do we come from? Is our destiny determined by the genes we inherit? Do we all see the same blue color when we look at the sky? In this book Gottfried (Jeff) Schatz, the world-renowned biochemist, gives lucid – albeit often surprising – answers to universal questions and takes the reader on a fascinating journey of discovery across the boundaries of scientific disciplines. With passion and a keen sense of wonder he draws on philosophy, cultural history and art to formulate his reflections on the mystery of life. The key to understanding life is to be found in its chemistry, and he proves that this is no dry endeavor and certainly not devoid of beauty. The result is a collection of eloquently and poetically written essays dealing with key issues in the natural sciences. It will appeal not only to scientists, but also to all inquisitive minds, regardless of educational and professional background.

Schatz, G. (Basel)
A Matter of Wonder
What Biology Reveals about Us, Our World, and Our Dreams
XII + 190 p., 2 color fig., hard cover, 2011
CHF 29.– / EUR 21.50 / USD 29.00
Prices subject to change
EUR price for Germany, USD price for USA only

More information and sample essays at www.karger.com/schatz

Orders can be placed at agencies, bookstores or directly with the publisher.
Also available through Amazon.com.

“A collection of extraordinary essays, reminiscent in many ways – scope, erudition, clarity, occasional whimsicality and sassiness – of Stephen Jay Gould’s essays for Natural History”
Herbert Deinert (Cornell University, Ithaca, N.Y.)

“A remarkable fusion of science and humanism”
Eugene P. Kennedy (Harvard University, Boston, Mass.)
Chemotherapy

International Journal of Experimental and Clinical Chemotherapy

Founded 1959 as “Chemotherapia” by H.P. Kuemmerle and P. Rentchnick

Editor-in-Chief
G. Minotti, Rome

Associate Editors
G. Delogu, Rome
G. Graziani, Rome

Editorial Board
A.M. Biroccio, Rome
C. Chiesa, Rome
S. Gemma, Siena
S. Horkovics-Kovats, Kundl
S. Kohno, Nagasaki
C. Landersdorfer, Parkville, Vic.
P. Linder, Geneva
K. Machka, Munich
P. Menna, Rome
E. Monti, Busto Arsizio
K.G. Naber, Straubing
R. Nau, Göttingen
P. Preziosi, Rome
E. Salvatorelli, Rome
M. Sanguinetti, Rome
G. Sava, Trieste
G.M. Shah, Quebec, Que.
F. Sörgel, Nuremberg-Heroldsberg
J.C. Stingl, Bonn
F. Van Bambeke, Brussels
M. Wilhelm, Nuremberg

Paul Ehrlich
1854–1915

The founder of chemotherapy
Guidelines for Authors

Submission
Before submission, please read the Guidelines for Authors for specific requirements for manuscript preparation. Manuscripts written in English are considered and should be submitted online at www.karger.com/che (a link leads you to the Submission Website).

Submission of an article implies author agreement with the below Conditions. To be considered for publication, all manuscripts must be accompanied by a cover letter signed by all authors stating that the work has not been published, nor is it under consideration elsewhere, and that all authors approve the submission.

A Copyright Transfer Form, available on the Submission Website, with the corresponding author’s original (hand-written) signature must be received by the editorial office. Please print and sign the form, and upload it during submission (or fax or scan and email) to make it legally binding.

Names, postal and e-mail addresses of 4 international experts in the appropriate area of research should accompany each manuscript. At the Editors’ discretion, scientist(s) selected from this list may be invited to act as referee(s). Referees suggested should not be from the same institution as the author.

Presentation of manuscripts should follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see International Committee of Medical Journal Editors. Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication (April 2010 version). Available from: http://www.ICMJE.org).

In case of problems with submission, please contact:
che@karger.com
S. Karger AG – Medical and Scientific Publishers
Editorial Office “Chemotherapy”
Allschwilerstrasse 10
CH–4009 Basel (Switzerland)
Tel. +41 61 306 1361
Fax +41 61 306 1434

Conditions
All manuscripts are subject to editorial and peer review. Manuscripts are received with the explicit understanding that the work has not been published (wholly or in part), and is not under simultaneous consideration in any language elsewhere. Furthermore, all authors have made substantial contributions and confirm that they have seen and approved the manuscript submission. Submission of an article for publication implies the transfer of the copyright from the author to Karger Publishers upon acceptance. Accepted papers become the permanent property of Chemotherapy and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Conflict of Interest
Authors are required to disclose any sponsorship or funding arrangements related to the research presented in the manuscript and any possible conflicts of interest. A possible conflict of interest does not preclude consideration of a manuscript for publication, but the Editor might consider it appropriate to publish the disclosed information with the paper. All forms of support and financial involvement should be listed in the Acknowledgements section of the paper. The cover letter should certify that all forms of conflict of interest by all authors were clearly identified in the text.

Ethics
Research must comply with the guidelines for human studies and animal welfare regulations. Manuscripts reporting studies on human subjects should include evidence that the research was ethically conducted in accordance with the Declaration of Helsinki (World Medical Association; http://www.wma.net/en/30publications/10policies/b3/index.html). In particular, authors should state in the Materials and Methods section that subjects have given their informed written consent and that the study protocol was approved by an appropriate ethics committee. All patients should be identified by numbers or aliases, not by their real names. Authors should also state that animal experimentation was approved by an independent ethics committee. Copies of these guidelines and policy statements must be available for review by the editors if necessary.

Plagiarism Policy
Whether intentional or not, plagiarism is a serious violation. Karger Publishers defines plagiarism as reproduction of another work with at least 25% similarity and without citation. If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

Sections
Authors should indicate in the cover letter which manuscript type is being submitted for publication:

Original Papers: Full documented reports of original research that must describe full sets of significant, original experiments in current anti-infective and antitumor chemotherapy research. Abstract, Introduction, Materials and Methods, Results, and Discussion sections are required. Consideration for publication is based on originality, novelty, scientific soundness, and appropriate analysis (maximum 3,000 words, 80 references, plus tables/figures).

Reviews: Comprehensive, state-of-the-art papers covering a timely topic by experts in the field (maximum 4,000 words, plus tables/figures, references). Reviews are usually invited by the Editor but may be unsolicited. Authors are asked to contact the Editor-in-Chief before submission in order to avoid clashes with other pending reviews. All reviews are subject to peer review. An unstructured abstract of no more than 200 words is required.

Novel Insights from Clinical Practice: The journal only considers case reports that provide significant new insights into a clinical problem or with an extremely unusual clinical course. Submissions can be based around a case or a number of similar cases. The most important aspect of the presentation is that it should provide a new perspective on a recognized clinical scenario or represent an entirely new clinical condition. The novel aspects of the case(s) may be in the phenotype, the presentation, the investigation and/or the management. The manuscript should contain an unstructured abstract (maximum 150 words), introduction, case report and discussion section (maximum 2,000 words, maximum 2 tables or figures). Boxes containing bulleted points on Established Facts (what is already known) and Novel Insights (new information gained) are required on the first page of the report. These should highlight the novelty of the clinical observation.

Short Communications: Short reports, brief laboratory observations, and preliminary communications can be submitted for accelerated publication under Short Communications. They must present new findings of significant importance to justify their accelerated publication. Such communications should represent complete, original studies and should be arranged in the same way as full length manuscripts (maximum 1,600 words).

Letters to the Editor: Letters to the Editor are encouraged if they directly concern articles recently published in this journal. If accepted, the Editor reserves the right to submit such letters to the authors of the articles concerned prior to publication in order to allow them to respond in the same issue of the journal. In exceptional cases, Letters to the Editor may also address data published in another journal or general subjects related to matters discussed in the journal. No abstract is required (maximum 1,200 words).

Arrangement
The preferred word processing program is MS-Word. The cover letter, the manuscript, the tables and the figures must be submitted in separate files. The manuscript file must contain all the text elements in the following order: title page, abstract and key words, main text, acknowledgments, references, table and figure legends. Tables and figures should be submitted as separate files according to the instructions below. Automatic line numbering should be used consecutively from the title page through to the final page. All pages should be numbered, starting from the title page, including tables, figure legends and figures.

Title page: The first page must contain the concise title of the article along with a short title for use as a running head, the full names of the authors and their affiliations (department, institute, hospital, university etc. where the work was conducted). The full postal address, telephone and fax numbers, as well as the e-mail address of the author to whom correspondence should be sent must be given at the bottom of the title page.

Key words: Please supply 3–10 key words that reflect the content of the paper.

Abstract: Each original paper needs an abstract of up to 250 words structured with subheadings as follows: Background/Where, Methods, Results, Conclusions. Structured abstracts are not needed for Reviews and Novel Insights from Clinical Practice.

Footnotes: Footnotes should be avoided. When essential, they should be numbered consecutively and appear at the foot of the appropriate page.

Acknowledgements: Include all sources of funding for the research presented in the manuscript and substantive contributions of individuals regarding the research or manuscript. All possible conflicts of interest should also be given here.

Abbreviations: Abbreviations (with the exception of those clearly well-established in the field) should be explained when they are first used.

Units of measurement: Measurements should be expressed in SI units wherever possible.

Drug names: Use generic names of drugs (first letter: lower-case) wherever possible. Registered trade names (first letter: upper-case) should be marked with the superscript registration symbol ™ or ® when they are first mentioned.

Tables and illustrations: Tables and figures must be numbered (e.g. Figure 1, Figure 2) and submitted as separate files. Tables require a heading and figures a legend, which must provide sufficient information for either to stand alone. Each figure and table must be cited in the text numerically. Tables should be in Word format. b/w half-tone and color figures must have a final resolution of 300 dpi after scaling to final size, line drawings 1,200 dpi. Color figures must be in RGB format. All figures should be in a common format such as PDF, TIF, PNG, EPS or WMF. Vector graphics should be in PPT, AI or EPS format.
Color Illustrations
Online edition: Color figures are reproduced free of charge. In the print version, the figures are reproduced in black and white. Any colors in the text and figure legends should be avoided.

Print edition: Up to 6 color figures per page can be integrated within the text at CHF 960.00 per page.

References
Identity references in the text using Arabic numerals (in square brackets). Do not alphabetize; number references sequentially in the order cited in the text. Material submitted for publication but not yet accepted should be referred to as [unpublished data] and should not be included in the reference list. The reference list should only include those publications which are cited in the text. Authors' surnames should be followed by their initials with no punctuation other than a comma if not essential to the citation. Do not add abbreviations (e.g., et al.) if not essential to the citation. Do not citate all authors (if not possible include at least 3 authors followed by et al). Abbreviate journal names according to the list of journals indexed for MEDLINE on the NLM website. Also see International Committee of Medical Editors: Uniform Requirements for Manuscripts Submitted to Biomedical Journals (http://www.icmje.org).

Examples


Reference Management Software: The use of EndNote is recommended to facilitate formatting of citations and reference lists. The journal output style can be downloaded from http://endnote.com/downloads/styles.

Supplementary Material and Multimedia Files
Multimedia files and other supplementary files, directly relevant but not essential to the conclusions of a paper, enhance the online version of a publication and increase its visibility on the web. These files will undergo editorial review. The Editors reserve the right to limit the scope and length of the supplementary material. Multimedia and supplementary material should meet production quality standards for publication without the need for any modification or editing. Files should not exceed 10 Mb in size. Figures and tables need to have titles and legends, and all files should be supplied separately and labeled clearly. All supplementary material should be referred to in the main text. A DOI number will be assigned to supplementary material and it will be hosted online at https://karger.figshare.com under a CC BY license. Authors will be charged a processing fee of CHF 250.00 for supplementary material.

Chemotherapy

English Language Editing
For authors whose native language is not English, use of a professional language editing service prior to submission can help to avoid delays with the review process.

Digital Object Identifier (DOI)
A DOI number will be available as a unique identifier on the title page of each article. DOIs are useful for identifying and citing articles published online without volume or issue information (for more information, see www.doi.org).

Self-Archiving/Green Open Access
Karger permits authors to archive their pre-prints (i.e., peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution's internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:

• Be used for noncommercial purposes only
• Be linked to the final version on www.karger.com

Include the following statement:
“This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. CytoGenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/?doi=[insert DOI number].”

The author’s responsibility to fulfill these requirements.

It is the author's responsibility to fulfill these requirements.

Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Karger on the author's behalf (see Funding Organizations (NIH etc.)).

For self-archiving Author's ChoiceTM (Gold Open Access) articles, see Author's ChoiceTM.

Author’s ChoiceTM
Karger’s Author’s ChoiceTM service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

The final, published version of the article may be posted at any time and in any repository or on other websites, in accordance with the relevant Creative Commons license.

The final, published version of the article may be posted at any time and in any repository or on other websites, in accordance with the relevant Creative Commons license.

Reprints
An order form with a price list can be requested when returning the corrected proofs. Orders submitted after the issue is printed are subject to considerably higher prices.

Copying, Distribution, and Reuse
For copying, distribution, and reuse, please refer to the Karger Terms and Conditions of Use (http://www.karger.com/terms-and-conditions-use).

Funding Organizations (NIH etc.)
The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date.

As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMC CID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author's ChoiceTM, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders' requirements (including Wellcome Trust and RCUK) for submission to PMC. Authors should include information on their grants in the Acknowledgements section of their papers.

Copy Editing
Manuscripts accepted for publication by Karger Publishers are subject to copy editing.

Proofs
An email containing a link to the download of the proofs will be sent to the corresponding author. Proofs should be returned within 48 hours. Alterations made in proofs, other than the correction of printer’s (introduced) errors, are charged to the author and may require editorial approval.

Page Charges
There is no page charge for papers of 3 or fewer printed pages (including tables, illustrations and references). Authors are charged CHF 325.00 for each additional complete or partial printed page.

Reprints
Authors are charged CHF 325.00 for each additional complete or partial printed page.

Page Charges
There is no page charge for papers of 3 or fewer printed pages (including tables, illustrations and references). Authors are charged CHF 325.00 for each additional complete or partial printed page.

Reprints
Authors are charged CHF 325.00 for each additional complete or partial printed page.
Focusing on the special needs of AYA cancer patients

Tumors in Adolescents and Young Adults

Editors
Daniel P. Stark
Gilles Vassal

The field of adolescents and young adults (AYA) oncology is experiencing a very challenging time. This book is a guide to the key issues for any clinician and health professional managing AYA with cancer in Europe. Emphasis is on collaboration between adult and pediatric specialists. Authors present their perception of the current state of the most prominent primary issues in AYA oncology.

Chapters cover cross-cutting issues such as disease epidemiology, systems of care, access to innovative therapy and late effects of treatment and survivorship for AYA-onset cancers. There are discussions of the latest developments and the most important cancer types in AYA, including the shared perspectives of adult and pediatric specialists. Throughout the book recurrent challenges to the AYA community are exposed and solutions proposed.

Tumors in Adolescents and Young Adults is highly recommended to any oncologist or hematologist treating patients aged 15 to 39 diagnosed with cancer. It will also be of interest to other members of the multidisciplinary teams involved with this patient group.

Contents
Preface: Stark, D.P.; Vassal, G.

Cross-Cutting Issues
- Epidemiology of Adolescents and Young Adults with Cancer in Europe: Desandes, E.; Stark, D.P.
- Supportive Care: Olsen, P.R.; Lorenzo, R.
- Long-Term Follow-Up and Survivorship: Tsirou, A.; Hjorth, L.
- Increasing Access to Clinical Trials and Innovative Therapy for Teenagers and Young Adults with Cancer – A Multiple Stakeholders and Multiple Steps Process: Gaspar, N.; Fern, L.
- Collaboration and Networking: Husson, O.; Manten-Horst, E.; van der Graaf, W.T.A.

Specific Illnesses
- Adult Cancers in Adolescents and Young Adults: Laurence, V.; Marples, M.; Stark, D.P.
- Pediatric Cancers and Brain Tumors in Adolescents and Young Adults: McCabe, M.G.; Valteau-Couanet, D.
- Leukemia: Juliusson, G.; Hough, R.
- Lymphoma in Adolescents and Young Adults: Brugières, L.; Brice, P.
- Germ Cell Tumors in Adolescents and Young Adults: Calaminus, G.; Joffe, J.
- Sarcomas of Soft Tissue and Bone: Ferrari, A.; Dirksen, U.; Bielack, S.

Author Index
Subject Index

The easiest way to order: www.karger.com/pritr
Issues in Infectious Diseases

Infections are a constant threat to human health. Over the last two decades a number of new infective agents such as HIV and prions have been identified, and several infectious diseases previously considered under control have suddenly reemerged. The problem of infection is aggravated by the resistance of many microorganisms to currently available antivirals and by the growing number of immuno-compromised people worldwide. The steadily rising incidence of nosocomial infections is a further cause for concern. This series presents original data and reviews the latest clinical information on infectious diseases of bacterial, viral, fungal and parasitic origin. Covering epidemiology, pathogenesis, prevention and treatment, it also considers the latest diagnostic techniques, evaluates new antimicrobial drugs and reports recent advances in vaccine development. As infections involve almost all branches of medicine, books published in this series represent a valuable source of information for a wide spectrum of clinicians and health care professionals.

Monographs in Virology

A skilful selection of topics of exceptional importance and a panel of acknowledged experts as authors have ensured an outstanding reputation for this series. Each monograph, centered on an active area of virologic research, provides a critical evaluation of recent progress and a useful commentary on the direction of future research. Characterized by a consistently high standard of scholarship and clear presentation of content, volumes in this series have proved their enduring value as convenient reference books for virologists and non-virologists alike.

**Online prices for institutional purchase**

Prices subject to change; VAT not included. EUR price for eurozone countries, USD price for USA and Latin America only.

**Online prices for personal customer**

Prices subject to change; VAT not included. EUR price for eurozone countries, USD price for USA and Latin America only.
Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.

Oncology
International Journal of Cancer Research and Treatment

Editor-in-Chief
M. Markman,

Regional Editor Japan
O. Hino, Tokyo

Selected contributions
• Use of Palliative Endocrine Therapy in Patients with Hormone Receptor-Positive Distal Metastatic Breast Cancer: How Often, How Effective, How Long? Güth, U. (Winterthur/Basel); Huang, D.J.; Schöttzau, A. (Basel); Schmid, S.M. (Grabs)
• Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061: Cerbone, L.; Sternberg, C.N. (Rome); Sengelov, L. (Herlev); Agerbaek, M. (Aarhus); Van Herpen, C. (Nijmegen); Marreaud, S.; Collette, S. (Brussels); Zhang, J. (Research Triangle Park, N.C.); Daugaard, G. (Copenhagen)
• A Comparison of the Hot Spot and the Average Cancer Cell Counting Methods and the Optimal Cutoff Point of the Ki-67 Index for Luminal Type Breast Cancer: Arima, N.; Nishimura, R.; Osako, T.; Nishiyama, Y.; Fujisue, M.; Okumura, Y.; Nakano, M.; Tashima, R.; Toyozumi, Y. (Kumamoto)
• Clinical and Emergent Biomarkers and Their Relationship to the Prognosis of Ovarian Cancer: Jatoi, A.; Vierkant, R.A.; Hawthorne, K.M.; Block, M.S. (Rochester, Minn.); Ramus, S.J. (Los Angeles, Calif.); Larson, N.B. (Rochester, Minn.); Fridley, B.L. (Kansas City, Kansas); Goode, E.L. (Rochester, Minn.)
• Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover – The Case of Pazopanib in Advanced Renal Cell Carcinoma: Diaz, J. (Uxbridge); Sternberg, C.N. (Rome); Mehmud, F. (Uxbridge); Delea, T.E. (Brookline, Mass.); Latimer, N. (Sheffield); Pandite, L. (Uxbridge); Motzer, R.J. (New York, N.Y.)
• Hepatocellular Carcinoma Extrahepatic Metastasis in Relation to Tumor Size and Alkaline Phosphatase Levels: Carr, B.I. (Izmir); Guerra, V. (Castellana Grotte)
• Umbilical Cord Blood Transplantation Is a Feasible Rescue Therapeutic Option for Patients Suffering from Graft Failure after Previous Hematopoietic Stem Cell Transplantation: Bojic, M. (Vienna) et al.

More information at www.karger.com/ocl
Antimicrobial Section

Original Papers

94 Determination of the Mutant Prevention Concentration and the Mutant Selection Window of Topical Antimicrobial Agents against Propionibacterium acnes
Nakase, K.; Nakaminami, H.; Toda, Y.; Noguchi, N. (Tokyo)

105 In vitro and in vivo Pharmacodynamics of Colistin and Aztreonam Alone and in Combination against Multidrug-Resistant Pseudomonas aeruginosa

121 Adaptive Cross-Resistance to Aminoglycoside Antibiotics in Pseudomonas aeruginosa Induced by Topical Dosage of Neomycin

128 Biofilm FormationRestrained by Subinhibitory Concentrations of Tigecyclin in Acinetobacter baumannii Is Associated with Downregulation of Efflux Pumps

Short Communication

100 Assessment of Fosfomycin for Complicated or Multidrug-Resistant Urinary Tract Infections: Patient Characteristics and Outcomes
Giancola, S.E.; Mahoney, M.V.; Hogan, M.D.; Raux, B.R.; McCoy, C.; Hirsch, E.B. (Boston, MA)

Anticancer Section

Review

111 Bevacizumab in Ovarian Cancer: State of the Art and Unanswered Questions
Musella, A.; Vertechy, L.; Romito, A.; Marchetti, C.; Giannini, A.; Sciuga, V.; Bracchi, C.; Tomao, F.; De Donato, V.; De Felice, F.; Monti, M.; Muzii, L.; Benedetti Panici, P. (Rome)

Original Papers

85 Lysosome Inhibitors Enhance the Chemotherapeutic Activity of Doxorubicin in HepG2 Cells
Li, Y.; Sun, Y.; Jing, L.; Wang, J.; Yan, Y.; Feng, Y.; Zhang, Y.; Liu, Z.; Ma, L.; Dao, A. (Tianjin)

134 A Difference in the Incidences of Hypersensitivity Reactions to Original and Generic Taxanes
Ratanajarurisiri, T.; Sriuranpong, V.; Sitthideatphaiboon, P.; Poovoravan, N.; Vinayanuwat, C.; Parinyanitikul, N.; Angspatt, P.; Thawinwisan, W.; Tanasanvimon, S. (Bangkok)

Novel Insights from Clinical Practice

140 Bendamustine and Rituximab: Complete Response in a 62-Year-Old Female with an Aggressive Lymphoma and an Ejection Fraction of 20%
Alrifai, T.; Grant Szymanski, K.; Venugopal, P.; Mahon, B.; Okwuosa, T.; Karmali, R. (Chicago, IL)